Anebulo Pharmaceuticals Future Growth

Future criteria checks 0/6

Anebulo Pharmaceuticals is forecast to grow earnings and revenue by 9.9% and 63.4% per annum respectively while EPS is expected to grow by 13.9% per annum.

Key information

9.9%

Earnings growth rate

13.9%

EPS growth rate

Pharmaceuticals earnings growth	23.7%
Revenue growth rate	63.4%
Future return on equity	n/a
Analyst coverage	Low
Last updated	09 Apr 2024

Recent future growth updates

Recent updates

Is Anebulo Pharmaceuticals (NASDAQ:ANEB) In A Good Position To Deliver On Growth Plans?

Feb 18

Is Anebulo Pharmaceuticals (NASDAQ:ANEB) In A Good Position To Invest In Growth?

Jul 03

Companies Like Anebulo Pharmaceuticals (NASDAQ:ANEB) Are In A Position To Invest In Growth

Mar 07

We Think Anebulo Pharmaceuticals (NASDAQ:ANEB) Can Afford To Drive Business Growth

Nov 19

Anebulo Pharmaceuticals to launch private investment in public equity financing

Sep 26

Anebulo Pharmaceuticals GAAP EPS of -$0.10 misses by $0.03

Sep 09

Here's Why We're Not Too Worried About Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation

Jun 28

Companies Like Anebulo Pharmaceuticals (NASDAQ:ANEB) Are In A Position To Invest In Growth

Mar 15

Here's Why We're Not Too Worried About Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation

Nov 04

Anebulo Pharmaceuticals reports FQ3 results

Jun 21

Earnings and Revenue Growth Forecasts

NasdaqCM:ANEB - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
6/30/2026	N/A	-24	N/A	N/A	2
6/30/2025	N/A	-18	N/A	N/A	2
6/30/2024	N/A	-12	N/A	N/A	3
12/31/2023	N/A	-10	-10	-10	N/A
9/30/2023	N/A	-12	-10	-10	N/A
6/30/2023	N/A	-12	-10	-10	N/A
3/31/2023	N/A	-12	-9	-9	N/A
12/31/2022	N/A	-11	-8	-8	N/A
9/30/2022	N/A	-8	-7	-7	N/A
6/30/2022	N/A	-7	-5	-5	N/A
3/31/2022	N/A	-34	-7	-7	N/A
12/31/2021	N/A	-41	-6	-6	N/A
9/30/2021	N/A	-40	-6	-6	N/A
6/30/2021	N/A	-38	-5	-5	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ANEB is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ANEB is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ANEB is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ANEB is forecast to have no revenue next year.

High Growth Revenue: ANEB is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if ANEB's Return on Equity is forecast to be high in 3 years time

Anebulo Pharmaceuticals Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Price target decreased to US$8.00

Recent updates

Is Anebulo Pharmaceuticals (NASDAQ:ANEB) In A Good Position To Deliver On Growth Plans?

Anebulo Pharmaceuticals, Inc., Annual General Meeting, Nov 20, 2023

New major risk - Share price stability

Anebulo Pharmaceuticals, Inc. Appoints Richie Cunningham as CEO

New major risk - Financial position

Is Anebulo Pharmaceuticals (NASDAQ:ANEB) In A Good Position To Invest In Growth?

Companies Like Anebulo Pharmaceuticals (NASDAQ:ANEB) Are In A Position To Invest In Growth

Anebulo Pharmaceuticals, Inc. Announces Completion of Dosing and Preliminary Data from Part B of its Phase 2 Study of ANEB-001 for Acute Cannabinoid Intoxication

We Think Anebulo Pharmaceuticals (NASDAQ:ANEB) Can Afford To Drive Business Growth

Price target decreased to US$8.00

High number of new and inexperienced directors

Anebulo Pharmaceuticals, Inc. Appoints Nat Calloway as Class II Director

Anebulo Pharmaceuticals, Inc., Annual General Meeting, Oct 28, 2022

Anebulo Pharmaceuticals, Inc. announced that it has received $6.646748 million in funding from 22NW, LP, Nantahala Capital Management, LLC, Brightleaf Capital, ADAR1 Capital Management, LLC, and other investors

Anebulo Pharmaceuticals, Inc. announced that it expects to receive $6.646748 million in funding from 22NW, LP and other investors

Anebulo Pharmaceuticals, Inc. Announces Positive Interim Data for ANEB-001 from Part B of its Phase 2 Clinical Trial for Acute Cannabinoid Intoxication

Anebulo Pharmaceuticals to launch private investment in public equity financing

Anebulo Pharmaceuticals GAAP EPS of -$0.10 misses by $0.03

Anebulo Pharmaceuticals Announces Positive Topline Data for Aneb-001 from A Phase 2 Clinical Trial for Acute Cannabinoid Intoxication

High number of new and inexperienced directors

Here's Why We're Not Too Worried About Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation

Anebulo Pharmaceuticals, Inc.(NasdaqCM:ANEB) dropped from Russell Microcap Value Index

Anebulo Pharmaceuticals, Inc. Announces Topline Data for ANEB-001 from an Ongoing Phase 2 Clinical Trial for Acute Cannabinoid Intoxication on Tuesday July 5, 2022

Anebulo Pharmaceuticals, Inc. Appoints Kenneth Cundy as Chief Scientific Officer

Anebulo Pharmaceuticals, Inc. Appoints Kenneth Cundy as Chief Scientific Officer

Anebulo Pharmaceuticals Doses More Than Half of the Subjects in Part A of A Phase 2 Clinical Trial and Provides Guidance on IND Submission

Companies Like Anebulo Pharmaceuticals (NASDAQ:ANEB) Are In A Position To Invest In Growth

Anebulo Pharmaceuticals, Inc. Announces Initiation of Phase 2 Clinical Study Evaluating ANEB-001 for the Treatment of Acute Cannabinoid Intoxication

Here's Why We're Not Too Worried About Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation

Anebulo Pharmaceuticals, Inc Announces Completion of Manufacturing of ANEB-001 Capsules for Upcoming Phase 2 Clinical Trial

Anebulo Pharmaceuticals reports FQ3 results

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies